Evidence map›Paper›PMID 33906315›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2021

The Impact of Sorafenib in Combination with Transarterial Chemoembolization on the Outcomes of Intermediate-Stage Hepatocellular Carcinoma.

Masaki Kaibori, Hideyuki Matsushima, Morihiko Ishizaki, Hisashi Kosaka, Kousuke Matsui, Shuji Kariya, Kengo Yoshii, Mitsugu Sekimoto

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Masaki KaiboriDepartment of Surgery, Kansai Medical University, Hirakata, Osaka, Japan.
Hideyuki MatsushimaDepartment of Surgery, Kansai Medical University, Hirakata, Osaka, Japan.
Morihiko IshizakiDepartment of Surgery, Kansai Medical University, Hirakata, Osaka, Japan.
Hisashi KosakaDepartment of Surgery, Kansai Medical University, Hirakata, Osaka, Japan.
Kousuke MatsuiDepartment of Surgery, Kansai Medical University, Hirakata, Osaka, Japan.
Shuji KariyaDepartment of Radiology, Kansai Medical University, Hirakata, Osaka, Japan.
Kengo YoshiiDepartment of Mathematics and Statistics in Medical Sciences, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Mitsugu SekimotoDepartment of Surgery, Kansai Medical University, Hirakata, Osaka, Japan.
Kansai Medical University · JPKyoto Prefectural University of Medicine · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe investigated the treatment outcomes and hepatic reserve of transarterial chemoembolization (TACE)-refractory patients with recurrent advanced hepatocellular carcinoma (HCC) treated with TACE plus sorafenib.

methodsForty-one patients with intermediate-stage HCC defined as being TACE refractory on imaging were treated with sorafenib and TACE between 2009 and 2012 and comprised the combination treatment group. Twenty-nine patients who received repeated TACE after becoming refractory to TACE between 2005 and 2008 comprised the TACE continuation group.

resultsAlthough the interval between successive rounds of TACE was significantly shorter before the patients developed TACE refractoriness, it was significantly longer after the development of TACE refractoriness, in the combination treatment group compared with the TACE continuation group. The appearance of extrahepatic spread and/or vascular invasion differed significantly between the two groups. The median overall survival was significantly longer in the combination treatment group than in the TACE continuation group (20.5 vs. 15.4 months, respectively; hazard ratio = 2.04; 95% confidence interval = 1.20-3.48). The 3-year overall survival rate was 33.4% in the combination treatment group and 3.5% in the TACE continuation group. Downstaging of the Child-Pugh class was significantly less frequent in the combination treatment group than in the TACE continuation group. In COX proportional hazards analyses, sorafenib plus TACE resulted in a better prognosis compared with repeated TACE.

conclusionsTreatment with sorafenib plus TACE in TACE-refractory patients with intermediate-stage HCC resulted in longer intervals between TACE rounds, better maintenance of hepatic reserve, and significantly longer OS compared with repeated TACE.

Indexed as

Chemoembolization, TherapeuticAgedAged, 80 and overAntineoplastic AgentsCarcinoma, HepatocellularCombined Modality TherapyFemaleHumansLiver NeoplasmsMaleMiddle AgedNeoplasm StagingRetrospective StudiesSorafenibSurvival RateTreatment OutcomeAntineoplastic AgentsSorafenibIntermediate-stage hepatocellular carcinomasorafenibTransarterial chemoembolization-refractory

Identifiers

PMID33906315
PMCPMC8325117
OpenAlexW3158563308

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.